$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Has Olaparib been included in the national medical insurance? Detailed explanation of its medical insurance policies and drug purchasing suggestions
2026-02-01 22:25:32
Check Details
What diseases does Olaparib treat?
2026-02-01 22:25:32
Check Details
Overview of Olaparib Side Effects Patients Need to Know
2026-02-01 22:25:32
Check Details
Detailed explanation of the therapeutic efficacy and side effects of Olaparib against BRCA mutated cancers
2026-02-01 22:25:32
Check Details
Erdafitinib drug purchase guide: purchase channels, prices and medical insurance reimbursement status
2026-02-01 22:25:32
Check Details
Side effect management strategies during erdafitinib treatment
2026-02-01 22:25:32
Check Details
Brief description of indications and correct medication guide for erdafitinib
2026-02-01 22:25:32
Check Details
Detailed medication guide and precautions for the Lao version of generic erdafitinib
2026-02-01 22:25:32
Check Details
Which company's drug is Erdafitinib, and what is its latest price?
2026-02-01 22:25:32
Check Details
Guidelines for the use of generic erdafitinib in Laos
2026-02-01 22:25:32
Check Details
Overview of the applicable patient groups and treatment advantages of Regorafenib (Belvango)
2026-02-01 22:25:32
Check Details
A complete guide to purchasing authentic regorafenib (regorafenib)
2026-02-01 22:25:32
Check Details
1
2
...
1021
1022
1023
1024
1025
1026
1027
...
10224
10225
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Dosing Duration, Efficacy Comparison, and Long-Term Management
2
Belzutifan (Welireg): Comprehensive Guide to the First HIF-2α Inhibitor — Indications, Dosing, and Safety Monitoring
3
Encorafenib (Braftovi): Comprehensive Guide to BRAF V600 Inhibitor Indications, Dose Regimens by Tumor Type, and Administration Requirements
4
Tazemetostat: Mechanism, Standard Dosing, and the 2026 Global Withdrawal of the First-in-Class EZH2 Inhibitor
5
FDA Approves Orzeyful, the World's First Orexin Receptor Agonist for Narcolepsy Type 1, Ushering in a New Era of Root-Cause Therapy
6
Alpelisib vs Inavolisib: How to Choose Between Two PI3Kα Inhibitors in PIK3CA-Mutated Breast Cancer
7
Selumetinib: The First MEK1/2 Inhibitor Approved for Inoperable Plexiform Neurofibromas in NF1
8
FIGHT-302 Phase 3 Trial: First-Line Pemigatinib Significantly Improves PFS Over Chemotherapy in FGFR2-Rearranged Cholangiocarcinoma
9
Selpercatinib Dosing Guide: Weight-Based Precision Targeting for RET-Driven Tumors
10
Mitotane Side Effects: Understanding Key Risks in Adrenocortical Carcinoma Therapy
11
Ponatinib: A Third-Generation TKI Targeting BCR::ABL1 to Overcome Leukemia Drug Resistance
12
Axitinib: Indications, Mechanism of Action & Key Safety Warnings